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Abstract
The present study summarizes our experience in treating a patient with a suspected granulocyte colony-stimulating
factor (G-CSF)-producing squamous cell carcinoma (SCC) of the lower gingiva, which is a rather rare entity.
A 56-year-old woman underwent surgical excision of palate leukoplakia in 1996. In 2009, however, a leukoplakic
superficial tumor was detected in the lower left gingiva, for which the patient underwent gingivectomy. This was
subsequently diagnosed as SCC. The patient also underwent superselective arterial injection chemotherapy
combined with radiotherapy, after local recurrence was observed. The patient was subsequently found to have
bone metastasis. After chemotherapy combined with radiotherapy, the patient underwent segmental resection of
the lower left jaw, left supraomohyoid neck dissection, and lower jaw reconstruction using titanium plates.
Resection of the left femoral tumor and left total knee replacement were also performed. Computed tomography
scan performed 1 month after the surgeries revealed multiple lung, liver, spine, and subcutaneous metastases. The
patient also exhibited a sudden increase in her white blood cell (WBC) count and a fever that could not be
alleviated, despite treatment with antibacterial drugs. A G-CSF-producing tumor was therefore suspected. Serum
G-CSF level was high at 250 pg/ml.
The patient's WBC count increased to 32 × 103/ml and her general condition suddenly deteriorated, and she died as
a result of multiple organ failure. A final diagnosis of G-CSF-producing SCC of the lower gingiva was made based
on the patient's clinical course.
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Background
Solid malignancies are sometimes accompanied by
leukocytosis and other leukemoid symptoms, the mech-
anism of which is attributed to the production of gran-
ulocyte colony-stimulating factor (G-CSF) by the tumor
cells themselves [1,2]. The ratio at which the malignant
tumor accuracy is defined with accessory symptoms
such as leukocytosis is not yet clear. G-CSF-producing
tumors exhibit significant hyperplastic and metastatic
properties and have a very poor prognosis [3]. The
present study describes our experience in treating a pa-
tient who was thought to have a G-CSF-producing squa-
mous cell carcinoma (SCC) of the lower gingiva, after
she developed systemic metastases along with fever and
a sudden increase in the white blood cell (WBC) count.
Case presentation
The patient was a woman in her 56 years old who had
initially consulted our hospital in November 1996, at the
onset of leukoplakia. The patient’s major complaint was
the appearance of leukoplakic lesions corresponding to
left side first and second molar equivalent to palate gin-
giva. The patient had been previously diagnosed with
uterine polyps. Her family history was unremarkable.
The patient was examined at our department in late No-
vember 1996, following a referral from her local dentist,
who detected white lesions on the left palate during den-
tal treatment in mid-November of the same year. The
patient was diagnosed with leukoplakia, and the palatal
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December of the same year. The patient was subse-
quently followed up on an outpatient basis. In May
2006, white lesions were observed on the left buccal
mucosa and the patient was diagnosed with dysplasia.
The condition was treated with another surgical resec-
tion, and the patient was followed up as an outpatient.
In December 2008, a leukoplakic superficial tumor
appeared at left side lower canine, the first premolar
equivalency department buccal marginal gingiva.
The patient had moderate physique and was well-
nourished, and no swelling of the cervical lymph nodes
was observed. Leukoderma and erosion were observed
at left side lower canine, the first premolar equivalency
department buccal marginal gingiva. (Figure 1 upper).
Panoramic radiography findings did not reveal any re-
sorption of the lower jaw. Computed tomography (CT)
findings did not indicate any clear destruction of the
lower left jaw or lymph node enlargement, which could
be suggestive of metastasis to the neck.
The clinical diagnosis for the patient was tumor of
lower left gingiva. In January 2009, the patient underwentFigure 1 (Upper) Intraoral photo at initial consultation:
leukoderma and erosion were observed at left side lower
canine, the first premolar equivalent to palate of gingiva
(Lower) Intraoral photo at relapse: hemorrhagic leukoderma
and erosion were observed at left side lower canine, the first
premolar equivalent to palate of gingiva.an excisional biopsy, with resection of the lower left
gingiva tumor. Pathological analysis revealed well-
differentiated SCC of more than 20 mm (pT2). No
swelling of the cervical lymph nodes was observed.
Hemorrhagic leukoderma and erosion were observed at
left side lower canine, the first premolar equivalent to
palate gingiva. (Figure 1 lower). Panoramic radiography
revealed resorption of the lower jaw (Figure 2), and CT
showed clear destruction of the lower left jaw, but with-
out lymph node enlargement, which could be suggestive
of metastasis to the neck (Figure 3).
On relapse, the patient was clinically diagnosed with a
lower left gingiva tumor. The tumor recurred in the
lower left gingiva (rT4aN0M0) in July 2009. Systemic
chemotherapy was performed with 15 mg bleomycin
(BLM). Beginning in August 2009, the patient under-
went selective arterial injection chemotherapy, combined
with radiotherapy. The chemotherapy regimen consisted
of 100 mg cisplatin (CDDP), administered in 4 doses:
30 mg to the lingual artery, 40 mg to the facial artery,
10 mg to the inferior alveolar artery, and 20 mg to the
occipital artery. The radiotherapy regimen using Linac
consisted of a total of 64 Gray (Gy) irradiation, adminis-
tered bilaterally in 32 fractions, including levels I and
IIa. The patient then complained of pain in the left
femur. An imaging study indicated that the tumor had
metastasized to the left femur (Figure 4A and 4B); there-
fore, 300 mg/day of tegafur-uracil (UFT) in combination
with radiotherapy, consisting of bilateral irradiation of
45 Gy in 15 fractions, was applied to the metastasis. At
the beginning of November 2009, the patient underwent
systemic chemotherapy with 135 mg nedaplatin (CDGP)
and 90 mg docetaxel (DTX), followed by 300 mg/day
UFT at the end of the same month. At the beginning of
December 2009, the patient underwent segmental resec-
tion of the lower left jaw, left supraomohyoid neck dis-
section, and lower jaw reconstruction using titanium
plates. At the end of December in the same year, the
femoral tumor was surgically removed and a total knee
replacement was performed. CT performed 1 monthFigure 2 Panoramic radiograph at relapse. Bone absorption
observed at left side lower canine, the first premolar equivalent to
department gingiva.
Figure 3 CT scan at relapse. Osteolysis observed at left side lower
canine, the first premolar, the second premolar equivalent to
department gingiva.
Figure 5 CT findings showed multiple metastases to the lungs.
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(Figure 5), liver, spine, mediastinal lymph nodes, and ab-
dominal subcutaneous tissue (Figure 6). The patient sim-
ultaneously exhibited fever and a sudden increase in herFigure 4 (A) Flurodeoxyglucose (FDG)-PET/CT scan showed a dense a
Radiographic image of the left femur revealed bone absorption indicWBC count and C-reactive protein (CRP), which failed
to abate, despite treatment with the antibacterial drug
imipenem hydrate-cilastatin sodium. A G-CSF-
producing tumor was suspected; the serum G-CSF level
was high at 250 pg/ml (Figure 7). The patient's WBC
count eventually increased to 32 × 103/ml. Her generalccumulation in the left femur suggestive of tumor metastasis (B)
ative of metastasis.
Figure 6 CT findings showed metastases to the liver, spine,
mediastinal lymph nodes, and abdominal subcutaneous tissue
(indicated by the red circle).
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multiple organ failure in February 2010; a month since
the G-CSF producing tumor was diagnosed. Patient sur-
vived for 13 months from her time of tumor diagnosis
till her death and her period of survival was uneventful.
Pathological examination on relapse revealed well-
differentiated SCC. Immunostaining of the resected spe-
cimen in January 2009 confirmed the presence of G-Figure 7 Shift in WBC count, CRP, and body temperature.CSF-positive tumor cells. Staining of biopsy tissue in July
of the same year revealed the G-CSF-positive tumor cells
to be more pronounced (Figure 8).
Discussion
It is known that solid malignancies are rarely accompan-
ied by leukocytosis and other leukemoid symptoms, the
mechanism of which is attributed to the production of
G-CSF by the tumor cells themselves [1,2]. Inflamma-
tion, infection, and leukemia are all possible causes of
marked leukocytosis. However, there are also malignant
tumors that manifest as elevated WBC count that could
not be explained, as illustrated in a case study by Hughes
et al. in 1950 [3]. In Japan the first case of a G-CSF-
producing tumor in the lung was reported by Asano
et al. in 1977 [4]. In terms of site of onset, G-CSF-
producing tumors are most often reported in patients
with lung cancer [4,5], with other described cases in-
cluding cancer of the stomach [6], pancreas [7], skin [8],
kidneys [9], and uterine cervix [10,11]. However, there
are relatively few studies on G-CSF-producing tumors
occurring in the head and neck, including the upper jaw,
gums, thyroid, tongue, and parotid glands [12-14].
Diagnosis of G-CSF-producing tumors previously
required the use of cumbersome methods to demon-
strate G-CSF production by tumor cells. Such methods
included the in vitro colony formation assay, measure-
ment of G-CSF activity after transplanting tumors into
nude mice [4], and detection of G-CSF mRNA in tumor
cells [15]. Currently, however, diagnosis is relatively sim-
ple, because G-CSF production in tumor cells can be
Figure 8 G-CSF-positive cells were more pronounced in the biopsy tissue specimen obtained in July 2009 than in the surgical
specimen obtained in January 2009.
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with enzyme immunoassay (EIA), or by immunohisto-
chemical staining with rh-G-CSF antibodies [15].
Asano et al. proposed the following 4 criteria for diag-
nosing G-CSF-producing tumors: (1) marked granulocy-
tosis, mainly consisting of mature neutrophils, (2)
elevated serum and urine G-CSF levels, (3) normalization
of granulocyte count and G-CSF level following tumor
removal, and (4) demonstration of increased G-CSF in
the tumor [4]. The patient in the present study exhib-
ited an increased WBC count, up to 32 × 103/ml with
neutrophil count of 93 %, and an elevated serum G-CSF
level of 250 pg/ml (normal G-CSF range, <18.1 pg/ml).
G-CSF-positive tumor cells were identified using immu-
nohistochemical staining. Thus, the patient fulfilled 3 of
the 4 above-mentioned criteria, although normalization
of granulocyte count and G-CSF level following tumor
removal could not be determined. However, comparison
of the G-CSF-positive tumor cells in an immunohisto-
chemically stained specimen, surgically removed in
January 2009, with those of the biopsy tissue specimen
obtained in July of the same year, indicated a marked
increase in the number of positive cells of the latter
specimen. This finding, combined with the onset of
leukocytosis after surgery, suggested a marked prolifera-
tion of the patient's G-CSF-producing tumor cells after
resection of the tumor, leading to a diagnosis of G-CSF-
producing SCC of the lower gum.G-CSF-producing tumors are considered to have a
poor prognosis, due to the effects of G-CSF on prolifer-
ating tumor cells and enhancement of metastasis. G-CSF
may therefore accelerate the clinical progression of the
disease [16]. The patient in the present study also exhib-
ited sudden systemic metastasis after treatment, accom-
panied by deterioration of her general condition.
G-CSF acts on the bone marrow to increase the WBC
count, but does not directly trigger inflammatory
responses, such as fever and elevated CRP. However,
previous studies have also reported findings of inflam-
mation, inferring that a separate cytokine is simultan-
eously produced within the G-CSF-producing tumor, in
conjunction with the inflammatory response. A previous
report speculated that interleukin 6 (IL-6) could be the
cytokine responsible for these effects [17]. The report on
G-CSF-producing tumors accompanied by inflammatory
responses, such as fever and elevated CRP, revealed high
levels of serum IL-6. Similarly, the patient in the present
study also had a high serum IL-6 level of 32.5 pg/ml
(normal range, <4.0 pg/ml), suggesting that IL-6 is
involved in the onset of fever and elevated CRP. IL-6 has
been reported to promote G-CSF production [18].
Therefore, it is possible that IL-6 produced by the tumor
elicited the production of G-CSF. While intratumoral
G-CSF can be locally diagnosed with immunohistochem-
ical staining, no such established diagnostic method cur-
rently exists for IL-6. Demonstration of the existence of
IL-6-producing tumor cells would therefore require cul-
tivation of tumor cells and measurement of their IL-6 ac-
tivity, and will be the focus of a future study. The
findings of the present study indicate that in solid-
malignancy patients who develop leukocytosis, elevated
CRP, and fever, it is important to make an early differen-
tial diagnosis between inflammatory disease and G-CSF-
producing tumors. Early diagnosis and determination of
a therapeutic strategy are also desirable, so as to improve
prognosis.
Conclusion
The present paper summarized our experience in treat-
ing a patient with G-CSF-producing SCC of the lower
gum. The patient was diagnosed with a G-CSF-
producing tumor on the basis of leukocytosis, elevated
serum G-CSF, and G-CSF-positive tumor cells, immuno-
histochemically detected by anti-G-CSF antibodies, as
well as clinical findings.
Consent
Written informed consent was obtained from the patient
for publication of this case report and any accompanying
images. A copy of the written consent can be furnished
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